Iron and oxidative stress in cardiomyopathy in thalassemia

Free Radical Biology and Medicine

Volumn 88, Issue , 2015, Pages 3-9

  Berdoukas, Vasilios ^a   Coates, Thomas D ^a   Cabantchik, Zvi Ioav ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Free radicals; Iron cardiomyopathy; Iron chelation therapy; Iron overload; Labile cellular iron; Labile plasma iron; Reactive oxygen species; Thalassemia major; Transfusion

Indexed keywords

FERROPORTIN; HEPCIDIN; IRON; REACTIVE OXYGEN METABOLITE; IRON CHELATING AGENT; TRANSFERRIN;

ARTICLE; BLOOD TRANSFUSION; CARDIOMYOPATHY; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON THERAPY; IRON TRANSPORT; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; THALASSEMIA; THALASSEMIA MAJOR; CARDIOMYOPATHIES; COMPLICATION; DRUG EFFECTS; PATHOPHYSIOLOGY;

CARDIOMYOPATHIES; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; OXIDATIVE STRESS; THALASSEMIA; TRANSFERRIN;

EID: 84942990195     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2015.07.019     Document Type: Review

References (68)

1. J. Wang, and K. Pantopoulos Regulation of cellular iron metabolism Biochem. J. 434 2011 365 381
2. T.A. Rouault The role of iron regulatory proteins in mammalian iron homeostasis and disease Nat. Chem. Biol. 2 2006 406 414
3. M.W. Hentze, M.U. Muckenthaler, and N.C. Andrews Balancing acts: molecular control of mammalian iron metabolism Cell 117 2004 285 297
4. D.J. Lane, A.M. Merlot, M.L. Huang, D.H. Bae, P.J. Jansson, S. Sahni, D.S. Kalinowski, and D.R. Richardson Cellular iron uptake, trafficking and metabolism: key molecules and mechanisms and their roles in disease Biochim. Biophys. Acta 1853 2015 1130 1144
5. T. Ganz Systemic iron homeostasis Physiol. Rev. 93 2013 1721 1741
6. R.E. Fleming, and P. Ponka Iron overload in human disease N. Engl. J. Med. 366 2012 348 359
7. N.C. Andrews Disorders of iron metabolism N. Engl. J. Med. 341 1999 1986 1995
8. E. Gammella, P. Buratti, G. Cairo, and S. Recalcati Macrophages: central regulators of iron balance Metallomics 6 2014 1336 1345
9. S. Lakhal-Littleton, M. Wolna, C.A. Carr, J.J. Miller, H.C. Christian, V. Ball, A. Santos, R. Diaz, D. Biggs, R. Stillion, P. Holdship, F. Larner, D.J. Tyler, K. Clarke, B. Davies, and P.A. Robbins Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function Proc. Natl. Acad. Sci. USA 112 2015 3164 3169
10. X.H. Ge, Q. Wang, Z.M. Qian, L. Zhu, F. Du, W.H. Yung, L. Yang, and Y. Ke The iron regulatory hormone hepcidin reduces ferroportin 1 content and iron release in H9C2 cardiomyocytes J. Nutr. Biochem. 20 2009 860 865
11. B. Halliwell, and J. Gutteridge Free Radicals in Biology and Medicine 2007 Oxford Univ. Press London
12. Z.I. Cabantchik Labile iron in cells and body fluids: physiology, pathology, and pharmacology Front. Pharmacol 5 2014 45
13. A. Jacobs Low molecular weight intracellular iron transport compounds Blood 50 1977 433 439
14. M. Kruszewski Labile iron pool: the main determinant of cellular response to oxidative stress Mutat. Res. 531 2003 81 92
15. G.J. Anderson, D. Darshan, S.J. Wilkins, and D.M. Frazer Regulation of systemic iron homeostasis: how the body responds to changes in iron demand Biometals 20 2007 665 674
16. G.J. Anderson Mechanisms of iron loading and toxicity Am. J. Hematol. 82 2007 1128 1131
17. C. Hershko Iron loading and its clinical implications Am. J. Hematol. 82 2007 1147 1148
18. Cabantchik, Z.I., S.Y., Breuer, W., Esposito, B. The Molecular and Cellular Basis of Iron Toxicity in Iron Overload Disorders: Diagnostic and Therapeutic Approaches.2013.
19. C. Hershko, G. Graham, G.W. Bates, and E.A. Rachmilewitz Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity Br. J. Haematol. 40 1978 255 263
20. W. Breuer, C. Hershko, and Z.I. Cabantchik The importance of non-transferrin bound iron in disorders of iron metabolism Transfus. Sci. 23 2000 185 192
21. P. Brissot, M. Ropert, C. Le Lan, and O. Loreal Non-transferrin bound iron: a key role in iron overload and iron toxicity Biochim. Biophys. Acta 1820 2012 403 410
22. A.M. Kolb, N.P. Smit, R. Lentz-Ljuboje, S. Osanto, and J. van Pelt Non-transferrin bound iron measurement is influenced by chelator concentration Anal. Biochem. 385 2009 13 19
23. D.H. Lee, D.Y. Liu, D.R. Jacobs Jr, H.R. Shin, K. Song, I.K. Lee, B. Kim, and R.C. Hider Common presence of non-transferrin-bound iron among patients with type 2 diabetes Diabetes Care 29 2006 1090 1095
24. G. Zanninelli, W. Breuer, and Z.I. Cabantchik Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients Br. J. Haematol. 147 2009 744 751
25. Z.I. Cabantchik, and E. Rachmilewitz Labile iron: potential toxicity in iron overload disorders Hematologist 12 2015 6
26. I. Slotki, and Z.I. Cabantchik The labile side of iron supplementation in CKD J. Am. Soc. Nephrol 2015
27. F. Danjou, Z.I. Cabantchik, R. Origa, P. Moi, M. Marcias, S. Barella, E. Defraia, C. Dessi, M.L. Foschini, N. Giagu, G.B. Leoni, M. Morittu, and R. Galanello A decisional algorithm to start iron chelation in patients with beta thalassemia Haematologica 99 2014 e38 e40
28. G. Link, and C. Hershko Rat heart cells in culture: a model of iron toxicity and chelation J. Lab. Clin. Med. 122 1993 14 15
29. J. Moreb, C. Hershko, and Y. Hasin Effects of acute iron loading on contractility and spontaneous beating rate of cultured rat myocardial cells Basic Res. Cardiol. 83 1988 360 368
30. H. Glickstein, R.B. El, M. Shvartsman, and Z.I. Cabantchik Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells Blood 106 2005 3242 3250
31. D.M. Templeton, and Y. Liu Genetic regulation of cell function in response to iron overload or chelation Biochim. Biophys. Acta 1619 2003 113 124
32. R. Crichton,. Inorganic Biochemistry of Iron Metabolism from Molecular Mechanisms to Clinical Consequences 2014.
33. E. Miyazaki, J. Kato, M. Kobune, K. Okumura, K. Sasaki, N. Shintani, P. Arosio, and Y. Niitsu Denatured H-ferritin subunit is a major constituent of haemosiderin in the liver of patients with iron overload Gut 50 2002 413 419
34. M.P. Weir, J.F. Gibson, and T.J. Peters Haemosiderin and tissue damage Cell. Biochem. Funct. 2 1984 186 194
35. M. Kruszewski The role of labile iron pool in cardiovascular diseases Acta Biochim. Polon 51 2004 471 480
36. J.P. Munoz, M. Chiong, L. Garcia, R. Troncoso, B. Toro, Z. Pedrozo, J. Diaz-Elizondo, D. Salas, V. Parra, M.T. Nunez, C. Hidalgo, and S. Lavandero Iron induces protection and necrosis in cultured cardiomyocytes: role of reactive oxygen species and nitric oxide Free Radic. Biol. Med. 48 2010 526 534
37. 2+ channels in iron transport and iron-overload cardiomyopathy J. Mol. Med. 84 2006 349 364
38. E. Gammella, S. Recalcati, I. Rybinska, P. Buratti, and G. Cairo Iron-Induced Damage in Cardiomyopathy:Oxidative-Dependent and Independent Mechanisms Oxidative Medicine and Cellular Longevity Volume 2015 Article ID 30182, http://dx.doi.org/10.1155/2015/230182
39. M.P. Chen, Z.I. Cabantchik, S. Chan, G.C. Chan, and Y.F. Cheung Iron overload and apoptosis of HL-1 cardiomyocytes: effects of calcium channel blockade PLoS One 9 2014 e112915
40. N. Chattipakorn, K.S. Fucharoen, and S. Chattipakorn S. Calcium channels and iron uptake into the heart World J. Cardiol. 3 2011 215 218
41. S. Kumfu, S. Chattipakorn, K. Chinda, S. Fucharoen, and N. Chattipakorn T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice Eur. J. Haematol. 88 2012 535 548
42. J.P. Liuzzi, F. Aydemir, H. Nam, M.D. Knutson, and R.J. Cousins Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc. Natl. Acad. Sci. USA 103 2006 13612 13617
43. S. Kumfu, S. Chattipakorn, S. Srichairatanakool, J. Settakorn, S. Fucharoen, and N. Chattipakorn T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice Eur. J. Haematol. 86 2011 156 166
44. T.A. Rouault Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease Dis. Models Mech 5 2012 155 164
45. O. Kakhlon, W. Breuer, A. Munnich, and Z.I. Cabantchik Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation Can. J. Physiol. Pharmacol. 88 2010 187 196
46. Y. Liu, J.G. Parkes, and D.M. Templeton Differential accumulation of non-transferrin-bound iron by cardiac myocytes and fibroblasts J. Mol. Cell. Cardiol. 35 2003 505 514
47. X. Gao, M. Qian, J.L. Campian, J. Marshall, Z. Zhou, A.M. Roberts, Y.J. Kang, S.D. Prabhu, X.F. Sun, and J.W. Eaton Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload Free Radic. Biol. Med. 49 2010 401 407
48. C.J. Murphy, and G.Y. Oudit Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment J. Card. Failure 16 2010 888 900
49. Z.I. Cabantchik, A. Munnich, M.B. Youdim, and D. Devos Regional siderosis: a new challenge for iron chelation therapy Front. Pharmacol 4 2013 167
50. J.B. Porter Practical management of iron overload Br. J. Haematol. 115 2001 239 252
51. A. Aessopos, C. Fragodimitri, F. Karabatsos, A. Hatziliami, J. Yousef, A. Giakoumis, A. Dokou, E.D. Gotsis, V. Berdoukas, and M. Karagiorga Cardiac magnetic resonance imaging R2∗assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia Haematologica 92 2007 131 132
52. M.A. Tanner, R. Galanello, C. Dessi, M.A. Westwood, G.C. Smith, S.V. Nair, L.J. Anderson, J.M. Walker, and D.J. Pennell Myocardial iron loading in patients with thalassemia major on deferoxamine chelation J. Cardiovasc. Magn. Reson. 8 2006 543 547
53. C.K. Lee, M.R. Stockler, A.S. Coates, V. Gebski, S.J. Lord, and R.J. Simes Australian New Zealand Breast Cancer Trials, G. Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer Br. J. Cancer 102 2010 1341 1347
54. K.A. Payne, M.P. Desrosiers, J.J. Caro, J.F. Baladi, N. Lordan, I. Proskorovsky, K. Ishak, and D. Rofail Clinical and economic burden of infused iron chelation therapy in the United States Transfusion 47 2007 1820 1829
55. J.P. Carpenter, T. He, P. Kirk, M. Roughton, L.J. Anderson, S.V. de Noronha, M.N. Sheppard, J.B. Porter, J.M. Walker, J.C. Wood, R. Galanello, G. Forni, G. Catani, G. Matta, S. Fucharoen, A. Fleming, M.J. House, G. Black, D.N. Firmin St, T.G. Pierre, and D.J. Pennell On T2∗magnetic resonance and cardiac iron Circulation 123 2011 1519 1528
56. B. Modell, and V. Berdoukas The Clinical Approach to Thalassaemia 1984 Grune & Stratton New York
57. P. Kirk, M. Roughton, J.B. Porter, J.M. Walker, M.A. Tanner, J. Patel, D. Wu, J. Taylor, M.A. Westwood, L.J. Anderson, and D.J. Pennell Cardiac T2∗magnetic resonance for prediction of cardiac complications in thalassemia major Circulation 120 2009 1961 1968
58. T.D. Coates Physiology and pathophysiology of iron in hemoglobin-associated diseases Free Radic. Biol. Med. 72 2014 23 40
59. M.A. Tanner, R. Galanello, C. Dessi, G.C. Smith, M.A. Westwood, A. Agus, M. Roughton, R. Assomull, S.V. Nair, J.M. Walker, and D.J. Pennell A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance Circulation 115 2007 1876 1884
60. V. Berdoukas, G. Chouliaras, P. Moraitis, K. Zannikos, E. Berdoussi, and V. Ladis The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study J. Cardiovasc. Magn. Reson. 11 2009 20
61. D.J. Pennell, J.B. Porter, A. Piga, Y. Lai, A. El-Beshlawy, K.M. Belhoul, M. Elalfy, A. Yesilipek, Y. Kilinc, T. Lawniczek, D. Habr, M. Weisskopf, Y. Zhang, and Y. Aydinok Investigators, C. s. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA) Blood 123 2014 1447 1454
62. L.J. Anderson, M.A. Westwood, S. Holden, B. Davis, E. Prescott, B. Wonke, J.B. Porter, J.M. Walker, and D.J. Pennell Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2∗cardiovascular magnetic resonance Br. J. Haematol. 127 2004 348 355
63. L.J. Anderson, B. Wonke, E. Prescott, S. Holden, J.M. Walker, and D.J. Pennell Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia Lancet 360 2002 516 520
64. D.J. Pennell, V. Berdoukas, M. Karagiorga, V. Ladis, A. Piga, A. Aessopos, E.D. Gotsis, M.A. Tanner, G.C. Smith, M.A. Westwood, B. Wonke, and R. Galanello Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis Blood 107 2006 3738 3744
65. V. Berdoukas, S. Carson, A. Nord, A. Dongelyan, S. Gavin, T.C. Hofstra, J.C. Wood, and T. Coates Combining two orally active iron chelators for thalassemia Ann. Hematol. 89 2010 1177 1178
66. M.S. Elalfy, A.M. Adly, Y. Wali, S. Tony, A. Samir, and Y. Elhenawy Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron-overloaded young beta thalassemia major patients Eur. J. Haematol 2015
67. M. Puliyel, A.G. Mainous 3rd, V. Berdoukas, and T.D. Coates Iron toxicity and its possible association with treatment of cancer: lessons from hemoglobinopathies and rare, transfusion-dependent anemias Free Radic. Biol. Med. 79C 2015 343 351
68. V. Berdoukas, A. Nord, S. Carson, M. Puliyel, T. Hofstra, J. Wood, and T.D. Coates Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age Am. J. Hematol. 88 2013 E283 E285